摘要
目的比较人表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)联合化疗与EGFR-TKI联合贝伐珠单抗治疗EGFR突变晚期非小细胞肺癌(NSCLC)的效果。方法回顾性分析2016年10月至2020年10月于郑州大学附属肿瘤医院诊治的185例EGFR突变晚期NSCLC患者的临床资料,根据已行的治疗方案,将其分为EGFR-TKI联合贝伐珠单抗组(A+T组)71例和EGFR-TKI联合培美曲塞+铂类组(C+T组)114例,比较两组疗效。结果A+T组和C+T组的客观缓解率(ORR)分别为60.6%和45.6%(P=0.048),疾病控制率(DCR)分别为87.3%和90.4%(P=0.519),中位无进展生存时间(PFS)分别为15.10个月和18.74个月(P=0.045)。不良反应包括胃肠道反应(8.45%和37.71%,P<0.001)、骨髓抑制(35.21%和54.39%,P=0.011)、肝毒性(15.49%和18.42%,P=0.609)、皮肤反应(5.63%和0.88%,P=0.029)、蛋白尿(14.08%和2.63%,P<0.001)和高血压(16.90%和4.39%,P<0.001)。结论EGFR-TKI联合化疗作为EGFR突变晚期NSCLC的一线治疗方案更加有效。
Objective To compare the efficacy difference between epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKI)combined with chemotherapy and bevacizumab in advanced EGFR-mutated non-small cell lung cancer(NSCLC).Methods The clinical data of 185 advanced EGFR-mutated NSCLC treated in the Affiliated Cancer Hospital of Zhengzhou University from October 2016 to October 2020 were retrospectively analyzed.According to the existing treatment regimen,they were divided into bevacizumab combined with EGFR-TKI group(A+T group)(71 cases)and EGFR-TKI combined with pemetrexed+platinum group(C+T group)(114 cases).The efficacy of the two groups was compared.Results The objective response rates(ORR)of A+T group and C+T group were 60.6%and 45.6%(P=0.048),disease control rates(DCR)were 87.3%and 90.4%(P=0.519)and median progression-free survival(PFS)were 15.10 and 18.74 months,respectively(P=0.045).The adverse reactions including gastrointestinal rection were 8.45%and 37.71%(P<0.001),myelosuppression were 35.21%and 54.39%(P=0.011),hepatotoxicity were 15.49%and 18.42%(P=0.609),rash were 5.63%and 0.88%(P=0.029),urine protein were 14.08%and 2.63%(P<0.001),and hypertension were 16.90%and 4.39%(P<0.001).Conclusion C+T is an efficient therapy for advanced NSCLC patients with EGFR activating mutation.
作者
焦书月
张潇
朱辉
汤虹
JIAO Shuyue;ZHANG Xiao;ZHU Hui;TANG Hong(Department of Respiratory Medicine,the Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital,Zhengzhou 450008,China)
出处
《河南医学研究》
CAS
2021年第35期6540-6544,共5页
Henan Medical Research
基金
河南省自然科学基金(212300410400)。
